Emergent therapy for acute－onset, severe hypertension during pregnancy and the postpartum period

doi:10.3877/cma.j.issn.2095-3259.2015.04.003

Abstract

Abstract:

Acute-onset, severe hypertension during pregnancy and the postpartum period is one of the main causes of peripartum death, which requires standardized and effective management for severe systolic and diastolic hypertension. In this article, we reviewed the progress in the management of acute-onset, severe hypertension and the common complication——HELLP syndrome during pregnancy and the postpartum period.

Key words: Hypertension, malignant, Eclampsia, Pregnancy complications, Hypotension, controlled

Yao Fan, Dongrui Deng. Emergent therapy for acute－onset, severe hypertension during pregnancy and the postpartum period[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2015, 04(04): 200-205.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2015.04.003

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/200

References 42

[1]	Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review[J]. 2006, 367(9516):1066-1074.
[2]	Madeiro AP, Rufino AC, Lacerda EZ, et al. Incidence and determinants of severe maternal morbidity: a transversal study in a referral hospital in Teresina, Piaui, Brazil[J]. BMC Pregnancy Childbirth, 2015, 15:210.
[3]	Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period[J]. Obstet Gynecol, 2015, 125(2):521-525.
[4]	Olson-Chen C, Seligman NS. Hypertensive Emergencies in Pregnancy[J]. Crit Care Clin, 2016, 32(1):29-41.
[5]	Too GT, Hill JB. Hypertensive crisis during pregnancy and postpartum period[J]. Semin Perinatol, 2013, 37(4):280-287.
[6]	Clark SM, Dunn HE, Hankins GD. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy[J]. Semin Perinatol, 2015, 39(7):548-555.
[7]	Magee LA, Namouz-Haddad S, Cao V, et al. Labetalol for hypertension in pregnancy[J]. Expert Opin Drug Saf, 2015, 14(3):453-461.
[8]	中华医学会妇产科学分会妊娠期高血压疾病组学. 妊娠期高血压疾病诊治指南(2015)[J]. 中华妇产科杂志，2015, 50(10):721-728.
[9]	Firoz T, Magee LA, Macdonell K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review[J]. BJOG, 2014, 121(10):1210-1218.
[10]	Xie RH, Guo Y, Krewski D, et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 175:124-128.
[11]	Meidahl PK, Jimenez-Solem E, Andersen JT, et al. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study[J]. BMJ Open, 2012, 2(4). pii: e001185.
[12]	Tsatsaris V, Cabrol D, Carbonne B. Pharmacokinetics of tocolytic agents[J]. Clin Pharmacokinet, 2004, 43(13):833-844.
[13]	Arulkumaran N, Lightstone L. Severe pre-eclampsia and hypertensive crises[J]. Best Pract Res Clin Obstet Gynaecol, 2013, 27(6):877-884.
[14]	Alexander JM, Wilson KL. Hypertensive emergencies of pregnancy[J]. Obstet Gynecol Clin North Am, 2013, 40(1):89-101.
[15]	Shi Q, Leng W, Yao Q, et al. Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy[J]. Int J Cardiol, 2015, 178:162-164.
[16]	Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade[J]. Br J Obstet Gynaecol, 1994, 101(3):262-263.
[17]	Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia[J]. Am J Obstet Gynecol, 2005, 193(1):153-163.
[18]	Al KK, Sequeira RP, Alkhaja AK, et al. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations[J]. J Hypertens, 2014, 32(3):454-463.
[19]	Delgado De Pasquale S, Velarde R, Reyes O, et al. Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial[J]. Pregnancy Hypertens, 2014, 4(1):19-22.
[20]	Nij BS, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature[J]. Obstet Gynecol Surv, 2010, 65(5):341-347.
[21]	Hanff LM, Vulto AG, Bartels PA, et al. Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients[J]. J Hypertens, 2005, 23(12):2319-2326.
[22]	Nooij LS, Visser S, Meuleman T, et al. The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine[J]. Curr Pharm Biotechnol, 2014, 15(1):64-69.
[23]	Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines[J]. PLoS One, 2014, 9(12):e113715.
[24]	Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014[J]. Aust N Z J Obstet Gynaecol, 2015, 55(5):e1-e29.
[25]	Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus[J]. Cochrane Database Syst Rev, 2009, (1):CD004661.
[26]	Ganzevoort W, Rep A, Bonsel GJ, et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia[J]. BJOG, 2005, 112(10):1358-1368.
[27]	Brownfoot FC, Gagliardi DI, Bain E, et al. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth[J]. Cochrane Database Syst Rev, 2013, 8:CD006764.
[28]	Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments[J]. Am J Obstet Gynecol, 2004, 190(4):878-881.
[29]	Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review[J]. BMC Pregnancy Childbirth, 2009, 9:8.
[30]	Kattah AG, Garovic VD. The management of hypertension in pregnancy[J]. Adv Chronic Kidney Dis, 2013, 20(3):229-239.
[31]	Dennis AT, Chambers E, Serang K. Blood pressure assessment and first-line pharmacological agents in women with eclampsia[J]. Int J Obstet Anesth, 2015, 24(3):247-251.
[32]	Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women[J]. Curr Hypertens Rep, 2011, 13(5):338-346.
[33]	ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002[J]. Obstet Gynecol, 2002, 99(1):159-167.
[34]	Duhig KE, Shennan AH. Recent advances in the diagnosis and management of pre-eclampsia[J]. F1000Prime Rep, 2015, 7:24.
[35]	Duhig KE, Shennan AH. CORRIGENDUM TO: Recent advances in the diagnosis and management of pre-eclampsia[J]. F1000Prime Rep, 2015, 7.pii: 24.
[36]	Ertan AK, Wagner S, Hendrik HJ, et al. Clinical and biophysical aspects of HELLP-syndrome[J]. J Perinat Med, 2002, 30(6):483-489.
[37]	Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count[J]. Obstet Gynecol, 2004, 103(5 Pt 1):981-991.
[38]	Martin JJ. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia)[J]. Int J Gynaecol Obstet, 2013, 121(3):202-207.
[39]	Woudstra DM, Chandra S, Hofmeyr GJ, et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy[J]. Cochrane Database Syst Rev, 2010, (9):CD008148.
[40]	Martin JJ, Thigpen BD, Rose CH, et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome[J]. Am J Obstet Gynecol, 2003, 189(3):830-834.
[41]	Gul A, Cebeci A, Aslan H, et al. Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome[J]. Gynecol Obstet Invest, 2005, 59(2):113-118.
[42]	Dusse LM, Alpoim PN, Silva JT, et al. Revisiting HELLP syndrome[J]. Clin Chim Acta, 2015, 451(Pt B):117-120.

Please choose a citation manager

Content to export